Real-time Estimate
Cboe BZX
07:37:53 06/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
26.06
USD
|
-1.47%
|
|
+4.40%
|
+184.94%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
957.7
|
1,115
|
1,474
|
670.6
|
2,529
|
-
|
-
|
Enterprise Value (EV)
1 |
629.5
|
709.2
|
863.7
|
670.6
|
1,808
|
2,098
|
2,529
|
P/E ratio
|
-12.4
x
|
-8.34
x
|
-6.64
x
|
-3.11
x
|
-8.43
x
|
-7.49
x
|
-8.29
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
141
x
|
120
x
|
160
x
|
70.1
x
|
188
x
|
241
x
|
29.8
x
|
EV / Revenue
|
92.8
x
|
76
x
|
93.6
x
|
70.1
x
|
134
x
|
200
x
|
29.8
x
|
EV / EBITDA
|
-14.3
x
|
-6.04
x
|
-4.87
x
|
-2.87
x
|
-6.8
x
|
-7.05
x
|
-
|
EV / FCF
|
-16.5
x
|
-7.2
x
|
-6.21
x
|
-
|
-7.77
x
|
-8.11
x
|
-11.8
x
|
FCF Yield
|
-6.07%
|
-13.9%
|
-16.1%
|
-
|
-12.9%
|
-12.3%
|
-8.5%
|
Price to Book
|
3.13
x
|
2.58
x
|
2
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
37,527
|
46,897
|
66,447
|
74,101
|
95,625
|
-
|
-
|
Reference price
2 |
25.52
|
23.77
|
22.19
|
9.050
|
26.45
|
26.45
|
26.45
|
Announcement Date
|
15/03/21
|
01/03/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.319
|
6.787
|
9.326
|
9.224
|
9.56
|
13.46
|
10.5
|
85.01
|
EBITDA
1 |
-
|
-43.9
|
-117.4
|
-177.5
|
-233.5
|
-265.9
|
-297.4
|
-
|
EBIT
1 |
-
|
-44.28
|
-118.1
|
-178.9
|
-235.6
|
-278.5
|
-317.7
|
-307.2
|
Operating Margin
|
-
|
-652.38%
|
-1,265.83%
|
-1,939.65%
|
-2,464.41%
|
-2,069.49%
|
-3,025.34%
|
-361.35%
|
Earnings before Tax (EBT)
1 |
-
|
-44.36
|
-118
|
-174
|
-212.2
|
-268.6
|
-315.5
|
-301.2
|
Net income
1 |
-
|
-44.36
|
-118
|
-174
|
-212.2
|
-269.6
|
-315.5
|
-301.2
|
Net margin
|
-
|
-653.53%
|
-1,265.38%
|
-1,886.33%
|
-2,219.87%
|
-2,003.19%
|
-3,005.06%
|
-354.28%
|
EPS
2 |
-4.320
|
-2.050
|
-2.850
|
-3.340
|
-2.910
|
-3.136
|
-3.533
|
-3.192
|
Free Cash Flow
1 |
-
|
-38.21
|
-98.55
|
-139.1
|
-
|
-232.6
|
-258.8
|
-215.1
|
FCF margin
|
-
|
-562.97%
|
-1,056.76%
|
-1,507.92%
|
-
|
-1,728.42%
|
-2,464.84%
|
-253.05%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/04/20
|
15/03/21
|
01/03/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
2.163
|
1.852
|
1.795
|
2.178
|
2.482
|
2.769
|
2.233
|
2.316
|
2.818
|
2.193
|
2.57
|
2.456
|
4.599
|
2.456
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-64.65
|
-58.92
|
-65.64
|
-78.41
|
-
|
EBIT
1 |
-29.28
|
-38.55
|
-34.46
|
-46.3
|
-44.93
|
-53.22
|
-57.6
|
-52.63
|
-58.62
|
-66.74
|
-67.42
|
-67.43
|
-68.96
|
-76.39
|
-
|
Operating Margin
|
-1,353.68%
|
-2,081.37%
|
-1,919.78%
|
-2,125.76%
|
-1,810.19%
|
-1,922.17%
|
-2,579.31%
|
-2,272.63%
|
-2,080.38%
|
-3,043.46%
|
-2,623.07%
|
-2,745.67%
|
-1,499.44%
|
-3,110.58%
|
-
|
Earnings before Tax (EBT)
1 |
-29.27
|
-38.54
|
-34.24
|
-45.69
|
-43.6
|
-50.47
|
-52.39
|
-47.02
|
-52.36
|
-60.44
|
-64.53
|
-65.77
|
-66.65
|
-71.67
|
-
|
Net income
1 |
-29.27
|
-38.54
|
-34.24
|
-45.69
|
-43.6
|
-50.47
|
-52.39
|
-47.02
|
-52.36
|
-60.44
|
-65.46
|
-65.93
|
-67.86
|
-70.31
|
-
|
Net margin
|
-1,353.4%
|
-2,080.89%
|
-1,907.24%
|
-2,097.8%
|
-1,756.61%
|
-1,822.72%
|
-2,346.35%
|
-2,030.44%
|
-1,857.98%
|
-2,756.18%
|
-2,546.9%
|
-2,684.48%
|
-1,475.6%
|
-2,863.07%
|
-
|
EPS
2 |
-0.6800
|
-0.8400
|
-0.7100
|
-0.9200
|
-0.8200
|
-0.8800
|
-0.7400
|
-0.6600
|
-0.7100
|
-0.7900
|
-0.8650
|
-0.8412
|
-0.8688
|
-0.8212
|
-0.8500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/21
|
01/03/22
|
10/05/22
|
09/08/22
|
08/11/22
|
28/02/23
|
09/05/23
|
08/08/23
|
08/11/23
|
28/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
328
|
406
|
611
|
-
|
722
|
431
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-38.2
|
-98.6
|
-139
|
-
|
-233
|
-259
|
-215
|
ROE (net income / shareholders' equity)
|
-
|
-36.8%
|
-34.3%
|
-36.3%
|
-
|
-102%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
8.150
|
9.210
|
11.10
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.09
|
3.74
|
2.82
|
4.23
|
0.4
|
0.42
|
0.44
|
Capex / Sales
|
-
|
16.09%
|
40.1%
|
30.6%
|
44.23%
|
2.97%
|
4%
|
0.52%
|
Announcement Date
|
03/04/20
|
15/03/21
|
01/03/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Last Close Price
26.45
USD Average target price
45.88
USD Spread / Average Target +73.44% Consensus |
1st Jan change
|
Capi.
|
---|
| +184.94% | 2.53B | | -3.89% | 88.14B | | +1.45% | 40.51B | | -15.24% | 31.67B | | +52.15% | 24.62B | | -14.47% | 15.65B | | -14.83% | 12.07B | | -9.12% | 11.97B | | -42.56% | 11.61B | | +5.09% | 8.81B |
Biopharmaceuticals
|